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milliliter. The median total 25OHD
concentration was 15.8 (IQR: 9.2–
26.6) ng/mL; 60.0% of patients had
vitamin D deﬁciency (,20 ng/mL);
and 28.8% had severe vitamin D
deﬁciency (,10 ng/mL). The median
25OHD2 concentration was 1.1 (,0.7
to 1.9) ng/mL, and the median 25OHD3
concentration was 14.2 (7.7–25.3)
ng/mL. The median percentage of total
25OHD that was 25OHD2 was 8.5
(4.5–16.0) percent. Consistent with
our earlier observations,8 we noted
associations between total 25OHD and
ethnicity, season of sampling, and es-
timated glomerular ﬁltration rate. By
contrast, 25OHD2 levels were unaf-
fected by age, gender, ethnicity, body
mass index, CD4 cell count, season
of sampling, or estimated glomerular
ﬁltration rate.
Our data conﬁrm the earlier
reported high prevalence of vitamin D
deﬁciency and severe vitamin D deﬁ-
ciency in our HIV-positive patients.8
None of the women in our cohort had
25OHD2 .4 ng/mL compared with 7%
of those studied by Adeyemi et al.1
This may relate to differences in food
fortiﬁcation practice, for example, milk
in the United States is typically fortiﬁed
with up to 400 IU per quart (385 IU/L)
of either vitamin D2 or D3, whereas no
vitamin D is added to milk in Britain.
The minimal contribution of 25OHD2
to total 25OHD levels in our study sug-
gests that previous studies using meth-
ods which may have underestimated
the contribution of 25OHD2 to total
25OHD concentrations are unlikely to
have signiﬁcantly overestimated the
prevalence of vitamin D deﬁciency.
For HIV-positive patients in the United
Kingdom, sunlight exposure and inges-
tion of vitamin D3 are the predominant
sources of vitamin D.
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Investigators
Involvement in the
Care of HIV-Infected
Individuals: The
Experience in Recent
Clinical Trials
To the Editors:
Highly active antiretroviral ther-
apy (HAART) has become the standard
for treating HIV infection.1 The intro-
duction of HAART resulted in an ap-
preciable decline in morbidity and
mortality due to HIV infection.2 An im-
provement in the life expectancy
among subjects with HIV infection re-
ceiving HAART has been reported
from low-income countries, such as
Uganda.3
In the December 2010 issue of
the Kennedy Institute of Ethics Journal,
Wendler and Abdoler4 raise the issue of
investigators’ intentions in conducting
clinical research and if this would even-
tually beneﬁt research subjects. The
authors conclude that “investigator
intentions per se are not relevant to
the ethics of clinical research”.
Over the last 30 years, research
on HIV/AIDS has been constellated of
many successes and failures, and there
remain with many challenges particu-
larly in prevention and treatment. As
Dieffenbach and Fauci5 have recently
pointed out, the critical elements in
controlling and ultimately ending the
HIV/AIDS pandemic are (1) seek, test,
and treat HIV-infected persons; (2) cure
at least a proportion of existing HIV
infections; and (3) prevent new infec-
tions with comprehensive combination
prevention programs. Recent experien-
ces in developed and undeveloped
countries have been reinforced by re-
cent demonstrations of HIV treatment
as prevention in the HIV Prevention
Trials Network (HPTN) 052 trial,
which shed more light in the ﬁeld of
preventing the spread of HIV/AIDS.6
In the article of Cohen et al,7 among
the 1763 couples with a discordant
HIV serological status enrolled in 9
countries who were randomized to re-
ceive an early or a delayed therapy,
a total of 39 HIV-1 transmission events
were observed and 28 of 39 were ge-
netically linked. Of these 28 linked
transmissions, 27 occurred in the
delayed-therapy group and only 1 in
the early-therapy group, giving a 96%
reduction in the rate of transmission.
All 27 transmissions in the delayed-
therapy group occurred when the
HIV-infected partner was not receiving
antiretroviral therapy. As the investiga-
tors underline, none of these results
could have been obtained without
a strong and enthusiastic involvement
of all physicians and nurses who con-
tributed to the trial, which was con-
ducted between 2007 and 2010.
Recently, other clinical trials
have been performed in settings where
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the sexual transmission of HIV is very
prevalent, such as the Centre for the
AIDS Program of Research in South
Africa (CAPRISA)8 and the Pre-Expo-
sure Prophylaxis Initiative (iPrEx)9 tri-
als. The intention-to-treat evaluation of
such trials did not reach the critical
50% efﬁcacy, nevertheless even small
reductions in transmitting HIV infec-
tion could be regarded as an important
breakthrough considering the deadly
toll of HIV. Because the 2 mentioned
studies were placebo controlled, their
optimistic ﬁndings posed renewed eth-
ical questions about placebo-controlled
trials to halt sexual transmission of
HIV.10
In HIV prevention trials, a pivotal
effort is to involve subjects and their
communities and physicians and nurses
in the active participation in the exper-
imental study from beginning to end.
As the Declaration of Helsinki states,
all potentially enrolled subjects must
be adequately informed on all aspects
related to the study and on the risks and
beneﬁts derived from the study treat-
ments and procedures.11 After this
point, no research is justiﬁed without
aiming to beneﬁt the single subject
who is enrolled in the trial. The Con-
vention of Oviedo (article 2) stresses
the supremacy of the human being
over any therapeutic intervention.12
HIV-infected individuals are deeply
affected by the disease, both physically
and psychologically, and, as care pro-
viders, we must always respect the
self-determination of a patient seeing
a physician who is proposing any clin-
ical trial. The understanding and the
assent of the subject to participate in
the clinical experiment is the responsi-
bility of the physician, and this respon-
sibility is ethically reinforced by the
patient’s informed consent. HIV patient
care involves a good amount of abilities
and emotional participation starting
from zidovudine monotherapy trials
back in the 80s to the newest random-
ized clinical trials in 2010–2011. Being
an infectious disease physician, the act
of enrolling a patient in a clinical trial
is already an act of responsibility
that you take because you ﬁrst and
foremost seek the good of that particu-
lar person. When you inform, get the
consent, and enroll your patient in
a clinical trial, you make a long-term
ethical evaluation.
In principle, the statement by
Hans Jonas could be agreed upon,
especially when he asserts that each
technology is an exercise of the human
power, is a “modus operandi”; all
human beings are subjected to a moral
exam.13 An ethical evaluation has to be
performed when we decide to design
and conduct any research activity: In
this case, it is more appropriate to talk
about an ethical evaluation, which
embraces a scientiﬁc examination given
to any research project.
Considering all the critical aspects
within HIV research, both in prevention
trials and in speciﬁc pharmaceutical
trials, we must take into consideration
all the ethical issues in protecting human
subjects involved in our clinical studies.
Most importantly, we should constantly
be involved, as recent trials have in-
dicated, in maintaining and updating the
patient–physician relationship to the
highest standard.
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